Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

Abstract

Alzheimer’s disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood–brain barrier. Nanotechnological treatment methods, which involve the design, characterization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via various routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease.

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

“…[92][93][94][95][96] Initially, SLN-or MSLN-loaded bioactive compounds were given intranasally or intravenously, and these showed extensive bioavailability in the brain, thereby preventing inflammation and further progression of AD. [97][98][99][100][101] Quercetin-loaded SLN with a particle size of about 200 nm was studied for its efficacy in the AD model, and it showed excellent delivery of quercetin to the brain with a higher antioxidative effect in brain cells.…”

Synthetic Polymer-Based Nanoparticles: Intelligent Drug Delivery Systems

“…It affects many people all over the world and their number increases rapidly. Fonseca-Santos et al [41] have presented an extended review about the significant benefits that intranasal polymer nanoparticle-based DDSs could ensure in the treatment of this disorder. Polymeric NPs (quinoline-n-butyl cyanoacrylate-based NPs, rivastigmine-loaded poly(n-butyl cyanoacrylate NPs) coated with polysorbate 80 and polysorbate 80-coated solid lipid NPs have been used for both diagnostic and treatment of Alzheimer's disease.…”

Liposome as nanocarrier: Site targeted delivery in lung cancer

“…Intranasal strategy for delivery of drugs to the brain appears as a revenue crammed course. For treating the cognitive impairments in Alzheimer's disease, recently approved drugs are based on neurotransmitter or enzyme inflection [33]. The intracellular delivery progress including lysosomal and mitochondrial targeting has also searched [34].…”